The Hematology ASH Education Program 2024 provides review articles from the Education Program at the 2024 ASH Annual Meeting. In this publication, each chapter relates to a different session presented at the meeting, spanning the spectrum from basic discovery and disease pathogenesis to the clinical application at the bedside.
This activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, and Novartis Pharmaceuticals Corp.
Cover: Illustration of the interaction of erythrocytes with plastic microparticles in blood, showing particle movement and deposition after entering the bloodstream via ingestion, inhalation, or absorption. Source: Kateryna Kon/Science Photo Library.
Featured Content
Sickle cell disease in India: the journey and hope for the future
Learning Objectives
- Summarize the current status of SCD in India, which has a high percentage of fetal hemoglobin accompanied by mild to severe complications
- Discuss the milestones and progress in understanding the SCD phenotype, accelerated by the National Sickle Cell Anaemia Elimination Mission 2023
The lasting impact of the ACA: how Medicaid expansion reduces outcome disparities in AYAs with leukemia and lymphoma
Learning Objectives
- Characterize the public health insurance programs in the post-ACA era that may impact AYAs with blood cancers
- Evaluate the implications of public health insurance programs in mitigating outcome disparities among AYAs with blood cancers
- Identify potential challenges that affect care access through the cancer control continuum among AYAs with blood cancers in the post-ACA era
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment
Learning Objectives
- Describe a framework for advancing health equity in pediatric oncology
- Describe examples of interventions targeted to social determinants of health with a focus on targeting poverty and unmet social needs